Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
Merck(MRK) stock is priced at $148.98, giving the company a market capitalization of 367.14B. It carries a P/E multiple of 118.92 and pays a dividend yield of 2.26%.
On 2026-09-29, Merck(MRK) stock moved within a range of $146.28 to $149.26. With shares now at $148.98, the stock is trading +1.8% above its intraday low and -0.2% below the session's peak.
Trading volume for Merck(MRK) stock has reached 7.7M, versus its average volume of 11.29M.
The stock's 52-week range extends from a low of $78.03 to a high of $156.92.
The stock's 52-week range extends from a low of $78.03 to a high of $156.92.
MRK News
...
Merck & Co. Inc. (NYSE:MRK) and healthcare company Daiichi Sankyo voluntarily pulled their U.S. Biologics License Application (BLA) seeking accelerated approval...
(RTTNews) - Merck & Co., Inc. (MRK), an American multinational pharmaceutical company, announced on Monday that it has entered into an exclusive global license...
Analyst ratings
68%
of 31 ratingsMore MRK News
Merck (MRK) and SciBrunch Therapeutics announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical o...
Merck (NYSE:MRK) and Eisai received FDA approval for Welireg plus Lenvima in previously treated advanced clear cell renal cell carcinoma. The new regimen is cl...
The Biologics License Application, or BLA, seeking accelerated approval in the U.S. for Daiichi Sankyo and Merck’s (MRK) ifinatamab deruxtecan for the treatment...
Merck (MRK) announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema, or DME. BRUNELLO is the first of two Pha...
Merck (MRK) is back in focus after fresh regulatory milestones, including an FDA label update for WINREVAIR in pulmonary arterial hypertension and new approvals...
Analyst Jason Gerberry from Bank of America Securities maintained a Buy rating on Merck & Company and keeping the price target at $166.00. Jason Gerberry has gi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.